Rhythm Pharmaceuticals (RYTM) PT Raised to $35 at BofA Securities
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
BofA Securities analyst Tazeen Ahmad raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $35.00 (from $33.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: RBC Capital Upgrades GMS Inc. (GMS) to Outperform
- Morgan Stanley Upgrades Shimamura Co Ltd (8227:JP) to Equalweight
- Cargotec Oyj (CGCBV:FH) (CYJBF) PT Raised to EUR48 at Morgan Stanley
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!